Philipp von Rosenstiel
Takeda (United States)(US)
Publications by Year
Research Areas
Multiple Sclerosis Research Studies, Sphingolipid Metabolism and Signaling, Peripheral Neuropathies and Disorders, Alzheimer's disease research and treatments, Acute Lymphoblastic Leukemia research
Most-Cited Works
- → Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial(2014)820 cited
- → Long-term effects of fingolimod in multiple sclerosis(2015)187 cited
- → Exacerbation of Apoptosis in the Dentate Gyrus of the Aged Rat by Dexamethasone and the Protective Role of Corticosterone(1996)179 cited
- → Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study(2015)163 cited
- → Adjunctive brivaracetam for refractory partial-onset seizures(2010)153 cited
- → Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis(2015)149 cited
- → Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis(2015)143 cited
- → Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial‐onset seizures: A phase IIb, randomized, controlled trial(2012)137 cited
- → Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study(2013)125 cited
- → Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings(2014)117 cited